Acute Parvovirus B19 Infection Mimicking Chronic fatigue Syndrome

Matano, Sadaya; Kinoshita, Hiroya; Tanigawa, Kiyoaki; Terahata, Shintaro; Sugimoto, Tatsuho

doi:10.2169/internalmedicine.42.903

Cited by 19 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such B19V associated clinical manifestations as fatigue, lymphadenopathy, joint and muscle pain in patients with ME/CFS could be consequences of the virus infection. Since B19V can cause typical clinical symptoms of ME/CFS, some studies report that this virus is one of the trigger factors for at least part of ME/CFS patients (Matano et al, 2003;Appel et al, 2007;Fremont et al, 2009), which coincides with the results of our study. ME/CFS can be caused by various factors, and some viruses or other infectious agents may contribute to a subset for this disease, confirming the hypothesis of B19V as a trigger factor for ME/CFS (Kerr et al, 2010).…”

Section: Discussionsupporting

confidence: 92%

Association of Human Parvovirus B19 Infection with Development and Clinical Course of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Rasa-Dzelzkalēja

Čapenko

Krūmiņa

et al. 2019

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

View full text Add to dashboard Cite

Our aim was to estimate the presence of B19V infection markers, the level of cytokines and time period since the appearance of infection in association with ME/CFS clinical symptoms. In 200 ME/CFS patients and 104 control group individuals the presence of B19V-specific IgG/IgM class antibodies, B19V NS1 gene sequence, mRNA expression, viral load and level of cytokines were determined. B19V-specific IgG-antibodies were found in 70% of ME/CFS patients and 67.4% of controls, IgM-antibodies in 8% of patients and in none of controls, B19V genomic sequences in 29% of patients and 3.8% of controls. 58.6% of positive patients had active and 41.4% had latent/persistent B19V infection. B19V NS1 gene expression was detected in 43% of patients. B19V load varied from < 0.2 copies to median 38.2 copies/µg of DNA. According to the antibody pattern, 36% of patients had a recent, and 43% had sustained B19V infection. Patients with the B19V genomic sequence and NS1 specific antibodies significantly more often had lymphadenopathy and multi-joint pain. Onset of the symptoms corresponded to time of appearance of B19V infection. IL-10 and TNF-levels were higher in patients with elevated B19V load. B19V genome 1 was identified in Latvian ME/CFS patients. The results indicated that at least in some cases B19V infection plays an important role in ME/CFS development

show abstract

Section: Discussionsupporting

confidence: 92%

Association of Human Parvovirus B19 Infection with Development and Clinical Course of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Rasa-Dzelzkalēja

Čapenko

Krūmiņa

et al. 2019

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

View full text Add to dashboard Cite

show abstract

“…80-87), peripheral neuropathy; 19 cases (no. [88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106], carpal tunnel syndrome (CTS); 10 cases (no. 107-116), Guillain-Barré syndrome (GBS); four cases (no.…”

Section: Discussionmentioning

confidence: 99%

Neurological aspects of human parvovirus B19 infection: a systematic review

Barah

Whiteside

Batista

et al. 2014

Reviews in Medical Virology

View full text Add to dashboard Cite

Parvovirus B19 has been linked with various clinical syndromes including neurological manifestations. However, its role in the latter remains not completely understood. Although the last 10 years witnessed a surge of case reports on B19-associated neurological aspects, the literature data remains scattered and heterogeneous, and epidemiological information on the incidence of B19-associated neurological aspects cannot be accurately extrapolated. The aim of this review is to identify the characteristics of cases of B19-associated neurological manifestations. A computerized systematic review of existing literature concerning cases of B19-related neurological aspects revealed 89 articles describing 129 patients; 79 (61.2%) were associated with CNS manifestations, 41 (31.8%) were associated with peripheral nervous system manifestations, and 9 (7.0%) were linked with myalgic encephalomyelitis. The majority of the cases (50/129) had encephalitis. Clinical characteristic features of these cases were analyzed, and possible pathological mechanisms were also described. In conclusion, B19 should be included in differential diagnosis of encephalitic syndromes of unknown etiology in all age groups. Diagnosis should rely on investigation of anti-B19 IgM antibodies and detection of B19 DNA in serum or CSF. Treatment of severe cases might benefit from a combined regime of intravenous immunoglobulins and steroids. To confirm these outcomes, goal-targeted studies are recommended to exactly identify epidemiological scenarios and explore potential pathogenic mechanisms of these complications. Performing retrospective and prospective and multicenter studies concerning B19 and neurological aspects in general, and B19 and encephalitic syndromes in particular, are required. © 2014 The Authors. Reviews in Medical Virology published by John Wiley & Sons, Ltd.

show abstract

“…Some controversy surrounds the clinical relevance of these initial findings, because the elec-tron micrographic appearance of parvoviruses can be confused with that of other gastrointestinal pathogens, such as astrovirus [14], and the particles were also found in asymptomatic children [1]. Parvovirus B19 is not considered to be an intestinal pathogen, although 2 case reports have described diarrhea in patients with active infection [15,16].…”

Section: Discussionmentioning

confidence: 99%